Jaguar Health receives hearing on Nasdaq listing compliance

Jaguar Health provided an update regarding the status of its listing with The Nasdaq Stock Market. “Jaguar requested a hearing to appeal a potential delisting of the Company’s securities from Nasdaq, and I’m pleased to report that a hearing has been scheduled, ” said Lisa Conte, Jaguar’s president and CEO. “The Company’s common stock will continue to trade on Nasdaq under the symbol ‘JAGX‘ pending the ultimate decision of any appeal process, and Jaguar’s board remains committed to taking all required steps to remain in compliance with Nasdaq’s listing standards.” As previously reported, on May 10, 2023 Jaguar was notified by Nasdaq’s Listing Qualifications Staff that the bid price for the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing on Nasdaq. The Company was granted a grace period until May 6, 2024, to regain compliance. On February 15, 2024, the Company received a letter from the Staff indicating that as of February 14, 2024, the Company’s common stock had a closing bid price of $0.10 or less for 10 consecutive trading days, subjecting the Company to the provisions of Nasdaq’s “Low Priced Stocks Rule,” and indicating Nasdaq’s intention to delist the Company’s securities from Nasdaq on February 26, 2024, unless the Company requests an appeal before the Nasdaq Hearings Panel.